Results 211 to 220 of about 10,059 (251)
Primary Candida glabrata Infection of a Pancreatic Pseudocyst. [PDF]
CureusBolanaki H +4 more
europepmc +1 more source
Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit. [PDF]
Antibiotics (Basel)Dermitzaki N +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2004
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David M Murdoch, Greg L. Plosker
+8 more sources
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David M Murdoch, Greg L. Plosker
+8 more sources
Reviews Of Anti‐infective Agents: Anidulafungin: A Novel Echinocandin [PDF]
Clinical Infectious Diseases, 2006 Until recently, the treatment available for serious fungal infections was composed of amphotericin B and azoles, and each class demonstrated significant limitations. Echinocandins are a new class of drugs that have shown promising results in treating a variety of fungal infections.
Jack D Sobel
exaly +4 more sources
Anidulafungin, a New Echinocandin [PDF]
Drugs, 2009 Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera.
G. Morace +3 more
openaire +7 more sources
Anidulafungin versus Fluconazole for Invasive Candidiasis [PDF]
New England Journal of Medicine, 2007 Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis.Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole.
Coleman Rotstein
exaly +3 more sources
Hospital Pharmacy, 2006
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Terri Levien +2 more
openaire +2 more sources
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Terri Levien +2 more
openaire +2 more sources
Anidulafungin: advantage for the newcomer?
Expert Review of Clinical Pharmacology, 2008Anidulafungin is the most recently approved compound of the echinocandin antifungal class. Its mode of action is the noncompetitive inhibition of β-(1,3)-D-glucan synthesis. Potent fungicidal activity has been demonstrated against many Candida spp., including non-albicansCandida spp.
Fedja Farowski +3 more
openaire +3 more sources
Expert Opinion on Drug Safety, 2006
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi.
openaire +3 more sources
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi.
openaire +3 more sources
Anidulafungin biliary passage in liver transplant patients
Transplant Infectious Disease, 2022We evaluated the anidulafungin passage in the bile by calculating the bile/plasma concentration ratios, and we assessed whether the ratios were influenced either by the time from administration or day of therapy. To this aim, a multiple linear GEE regression model (SAS software) was used, with the day of therapy and the hour after administration as ...
Adembri, Chiara +5 more
openaire +2 more sources